Medical Biotechnology Innovation In India

This book examines the medical biotechnology industry in India through the lens of a critical political economy. It discusses the sharp trajectory of growth in the biotechnology business and the state of investments, subsidies, and patents which propelled the rise of the industry in India. The book uses in-depth interviews and case studies to analyse the roles of various financial actors, state institutions, and academia in the medical biotechnology ecosystem. Focusing on the relationship between India’s neoliberal policies and the swift growth of the industry, the author examines the merits and demerits of the current market-driven biomedical ecosystem exploring the trends in the industry, biomedical start-ups, the use of human resources, and capital accumulation process. The book reiterates and emphasises the need for the democratisation of scientific and medical work and for striking a balance between economic gains and public health priorities. Comprehensive and insightful, this book will be of interest to scholars and researchers of science technology society studies, public health, economics, business studies, medical sociology, public policy, and political science.

This book examines the progress in the biotechnology sector in India towards knowledge and innovation driven Bioeconomy. The chapters of the book review different genome editing techniques and the GM crops focusing on the emerging potential in agricultural biotechnology. Chapters on Vaccines and AI in healthcare unfold huge opportunities in medical biotechnology. The book covers the advances in biotechnology towards delivering important benefits of healthcare, particularly through the pharmaceutical industry focusing on new healthcare interventions and delivering innovations. Further, it explores the major opportunities in industrial biotechnology related to bio-pharma, biorefinery, fermentation biotechnology, and growing synergies between industry-academia. Toward the end, the book also reviews the genetic regulation and the critical role of HRD. In summary, the book emphasizes on India as a strong bio-manufacturing hub for innovative, affordable and accessible products for the society and also for global markets while describing the sector wise strategies required.

Contemporary Medical Biotechnology Research for Human Health discusses a range of currently available solutions required to defeat the ever-increasing human health challenges. The junction between biotechnology and biomedical/health sciences has led to several improvements in patients’ treatment, diagnosis and well-being. The book discusses vital topics ranging from biofilms and UTI, mycobacterial infections, diabetes, aplastic anemia, oral cancer, and possible applications of nanoparticles. In addition, it discusses computer-aided drug design using natural products and new technologies to develop antibiotics. This is a valuable resource for biotechnology and biomedical researchers, bioinformaticians and members of health sciences interested in understanding recent technological developments. Bridges the gap between biotechnology and biomedical/health sciences in a holistic way to leverage multidisciplinary research Discusses the benefits of using potential microbes and natural products to improve health protection through biotechnological intervention Presents several case studies and practical applications of recent findings in the field in order to be easily applied by the readers

The biotechnology business in India with an increase from USD 500 million in 1997 and reaching an estimated USD I billion next year health related prod ucts accounting for 60%, agro and veterinary products together 15%, and con tract R&D, reagents, devices and supplies adding up to the remaining 25% of which the diagnostics share was about 10% of the total surely presented an encouraging picture even five years ago. While volumes have increased, the pat tern has not. According to a report, prepared by McKinsey & Co, India's Phar maceutical industry including domestic and export sales and contract services totals nearly USD 5 billion. Furthermore, the company optimistically projects the growth to a factor of five fold only if both the industry and the government are able to put in place achievable solutions that must take care of the formida ble obstacles preventing further growth. If this assessment is correct, then the established transformation made by IT growth should also provide the confi dence required by the high expectations for biotechnology which have arisen in the country in recent years. Some contributors to this are overenthusiastic these are bureaucrats, some retired scientists and of course the complacent politicians who have the least knowledge of what the new biotechnology is all about. However, there are clear indications of biotechnology growth demon strated by a few but rapidly expanding biotech companies such as Biocon Ltd, Shantha Biotech (P) Lid, Dr.

Examines the links between growth and inequality and discusses whether or not growth has been inclusive in recent experience in India.

The biotechnology business in India with an increase from USD 500 million in 1997 and reaching an estimated USD 1 billion next year health related prod ucts accounting for 60%, agro and veterinary products together 15%, and con tract R&D, reagents, devices and supplies adding up to the remaining 25% of which the diagnostics share was about 10% of the total surely presented an encouraging picture even five years ago. While volumes have increased, the pat tern has not. According to a report, prepared by McKinsey & Co, India's Phar maceutical industry including domestic and export sales and contract services totals nearly USD 5 billion. Furthermore, the company optimistically projects the growth to a factor of five fold only if both the industry and the government are able to put in place achievable solutions that must take care of the formida ble obstacles preventing further growth. If this assessment is correct, then the established transformation made by IT growth should also provide the confi dence required by the high expectations for biotechnology which have arisen in the country in recent years. Some contributors to this are overenthusiastic these are bureaucrats, some retired scientists and of course the complacent politicians who have the least knowledge of what the new biotechnology is all about. However, there are clear indications of biotechnology growth demon strated by a few but rapidly expanding biotech companies such as Biocon Ltd, Shantha Biotech (P) Ltd, Dr.

In terms of becoming a successful bioentrepreneur, there is still much more to learn. There are many ways to learn the essential fundamentals of entrepreneurship, including through the mistakes of previous businesses and models. Increased knowledge and a better understanding of what works can be derived from these previous failures and mistakes. Additionally, learning from other bioentrepreneurs can help businesses run successfully. By looking deeper into business models, product development, the fundamental concepts of bioentrepreneurship, and the essential characteristics of bioentrepreneurs, one can become better equipped to understand the role of biological sciences in entrepreneurship, specifically the role of product development. Bioentrepreneurship and Transferring Technology Into Product Development provides a comprehensive understanding of the role of biological sciences, specifically in transforming technology into commercial product. This book compiles the theoretical and practical aspects of bioentrepreneurship and discusses the various factors, including creating business plans, acquiring funding, and successful business models. The chapters also cover areas such as small-scale product development, intellectual property rights, funding schemes for start-ups, and new prospective biotechnology product development. This book is essential for bioentrepreneurs, entrepreneurs, product developers, scientists, practitioners, researchers, academicians, and students interested in product development from a biological science perspective.

Biotechnology in the Modern Medicinal System: Advances in Gene Therapy, Immunotherapy, and Targeted Drug Delivery presents an informative picture of the state-of-the-art research and development of actionable knowledge in medical biotechnology, specifically involving gene therapy, immunotherapy, and targeted drug delivery systems. The book includes novel approaches for therapy of various ailments and the real-world challenges and complexities of the current drug delivery methodologies and techniques. The volume helps to bridge the gap between academic research and real-time clinical applications and the needs of medical biotechnology methods. This edited book also provides a detailed application of medical biotechnology in drug discovery and the treatment of various deadly diseases. Chapters discuss targeted drug delivery to specific sites to avoid possible entry to non-targeted sites, minimizing adverse effects. The volume provides information about the roles of alternative routes of drug targeting, like intranasal and transdermal, resulting in improving patient compliance. Targeted drug delivery is explored for several health issues, such as neurodegenerative disorders, cancer, malaria, and hemoglobin disorders. Also considered is the role of genes in various genetic diseases and gene therapy, and immunogene therapy as alternative approaches to conventional cancer therapy. Finally, the book investigates the important role of computers in biotechnology to accelerate research and development in the modern medicinal field for better and optimum results. Studies show that significant improvement has been observed in the development of a faster and less invasive diagnostic system for the treatment of diseases by utilizing both artificial intelligence (AI) and biotechnology. This valuable volume provides a wealth of information that will be valuable to scientists and researchers, faculty, and students.

The biotechnology business in India with an increase from USD 500 million in 1997 and reaching an estimated USD I billion next year health related prod ucts accounting for 60%, agro and veterinary products together 15%, and con tract R&D, reagents, devices and supplies adding up to the remaining 25% of which the diagnostics share was about 10% of the total surely presented an encouraging picture even five years ago. While volumes have increased, the pat tern has not. According to a report, prepared by McKinsey & Co, India's Phar maceutical industry including domestic and export sales and contract services totals nearly USD 5 billion. Furthermore, the company optimistically projects the growth to a factor of five fold only if both the industry and the government are able to put in place achievable solutions that must take care of the formida ble obstacles preventing further growth. If this assessment is correct, then the established transformation made by IT growth should also provide the confi dence required by the high expectations for biotechnology which have arisen in the country in recent years. Some contributors to this are overenthusiastic these are bureaucrats, some retired scientists and of course the complacent politicians who have the least knowledge of what the new biotechnology is all about. However, there are clear indications of biotechnology growth demon strated by a few but rapidly expanding biotech companies such as Biocon Ltd, Shantha Biotech (P) Lid, Dr.